Base editors

| CRISPR Medicine | This is an overview of articles on base editors

Sign-up to weekly Newsletter here.

UK Medicines Regulator Awards Innovation Passport...

Feb. 15, 2023

Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the...

First Patient Is Dosed With Base Editor to Treat...

Aug. 17, 2022

Verve Therapeutics recently announced the first human dosing with VERVE-101, an investigational base-editing therapy that is designed to treat...

Disease Roundup: Genomic Medicine Candidates for...

Jul. 20, 2022

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

Clinical Update: Base-Editing Cholesterol-Reducing...

May. 18, 2022

Verve Therapeutics announced last week that its clinical trial application for VERVE-101 in heterozygous familial hypercholesterolemia had been...

Webinar

Controllable Genome Editing with Split-engineered...

Apr. 27, 2022

Read more about the webinar - Controllable Genome Editing with Split-engineered Base Editors

A Decade of CRISPR and a Promising Future -...

CMN Special

Feb. 21, 2022

In 2022, we celebrate a decade of CRISPR as a game-changing tool in research and medicine. The last 10 years have been phenomenal, and CRISPR cures...

Base Editing Slams the Door Shut on HIV

Jan. 31, 2022

A recent study reports the first ever application of base editing to protect immune cells against HIV infection. This is achieved without introducing...

Trends That Advanced CRISPR Therapies in 2021

Jan. 19, 2022

2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...